ES2074490T3 - Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa. - Google Patents

Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.

Info

Publication number
ES2074490T3
ES2074490T3 ES90105405T ES90105405T ES2074490T3 ES 2074490 T3 ES2074490 T3 ES 2074490T3 ES 90105405 T ES90105405 T ES 90105405T ES 90105405 T ES90105405 T ES 90105405T ES 2074490 T3 ES2074490 T3 ES 2074490T3
Authority
ES
Spain
Prior art keywords
preparation
procedure
via intravenous
immunoglobin
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90105405T
Other languages
English (en)
Other versions
ES2074490T5 (es
Inventor
Norbert Dr Dipl-Chem Kothe
Dieter Dr Dipl-Chem Rudnick
Detlef Dr Dipl-Chem Piechaczek
Herwald Dr Klein
Detlef Dr Dipl-Biol Rohm
Michael Dr Dipl-Chem Kloft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest Pharma GmbH
Original Assignee
Biotest Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8203787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2074490(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotest Pharma GmbH filed Critical Biotest Pharma GmbH
Publication of ES2074490T3 publication Critical patent/ES2074490T3/es
Application granted granted Critical
Publication of ES2074490T5 publication Critical patent/ES2074490T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

METODO Y ELABORACION DE UN PREPARADO G, QUE SOPORTA LA INMUNOGLOBINA INTRAVENENOSA, EL CUAL ESTA LIBRE DE GRUPOS, SUSTANCIAS VASOACTIVAS Y ENCIMAS PROTEOLITICAS Y ES APROPIADO PARA UN COLECTIVO DE PACIENTES, CONCRETAMENTE PARA LOS PACIENTES "INMUNOSUPRIMIDOS", QUE CONSTA DE UN MATERIAL DE SALIDA CON UN CONTENIDO G DE INMUNOGLOBINA, LIBRE DE FACTORES DE COAGULACION, CON UN TRATAMIENTO DE UN % DE VOLUMEN DE 0,4 A 1,5 DE ACIDOS DE OCTANO Y/O CON UNA CROMATOGRAFIA SIGUIENTE, ESPECIALMENTE, EN EL INTERCAMBIO DE CATIONES O ANIONES O DE UNA MATRIX DE CROMATOGRAFIA DE HIDROFOBEN.
ES90105405T 1990-03-22 1990-03-22 Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa. Expired - Lifetime ES2074490T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90105405A EP0447585B2 (de) 1990-03-22 1990-03-22 Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates

Publications (2)

Publication Number Publication Date
ES2074490T3 true ES2074490T3 (es) 1995-09-16
ES2074490T5 ES2074490T5 (es) 2004-02-16

Family

ID=8203787

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90105405T Expired - Lifetime ES2074490T5 (es) 1990-03-22 1990-03-22 Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.

Country Status (7)

Country Link
US (1) US5164487A (es)
EP (1) EP0447585B2 (es)
JP (1) JPH06107561A (es)
AT (1) ATE122054T1 (es)
DE (1) DE59009020D1 (es)
DK (1) DK0447585T4 (es)
ES (1) ES2074490T5 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
ES2527915T3 (es) * 1998-06-09 2015-02-02 Csl Behring Ag Producto de inmunoglobulina G (IgG) líquido
DE19904407C2 (de) 1999-02-04 2001-09-20 Bayer Ag Vorrichtung zum Wechseln einer Düsenplatte eines Prillturmes und Verfahren zum automatisierten Wechsel
SE0001128D0 (sv) * 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
EP1786827A4 (en) * 2004-05-14 2008-10-29 Kirin Holdings Kk PROCESS FOR IMMUNOGLOBULINE CLEANING
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
FR2895263B1 (fr) 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
NZ576262A (en) * 2006-11-01 2012-05-25 Biogen Idec Inc Method of isolating biomacromolecules using low ph and divalent cations
EP2152745B2 (en) 2007-06-01 2023-03-15 F. Hoffmann-La Roche AG Immunoglobulin purification
US8772461B2 (en) 2008-04-15 2014-07-08 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
US20090292109A1 (en) * 2008-04-16 2009-11-26 Biogen Idec Ma Inc. Method of Isolating Biomacromolecules Using Polyalkylene Glycol and Transition Metals
AU2011212440B2 (en) 2010-02-04 2015-01-22 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
EP2961761B1 (en) * 2013-02-28 2018-09-12 Agency For Science, Technology And Research Protein purification in the presence of nonionic organic polymers at elevated conductivity
KR20150123796A (ko) 2013-02-28 2015-11-04 에이전시 포 사이언스, 테크놀로지 앤드 리서치 크로마틴 결핍 세포 배양 수확물로부터의 항체들의 크로마토그래프 정제
DK3016976T3 (da) 2013-07-01 2020-12-07 Csl Behring Ag Proces
SG11201603028SA (en) 2013-10-18 2016-05-30 Universität Für Bodenkultur Wien Purification of proteins
JP6700197B2 (ja) 2014-04-30 2020-05-27 ノヴォ ノルディスク アー／エス カプリル酸を用いてタンパク質を精製する方法
KR101657690B1 (ko) * 2015-06-05 2016-09-19 주식회사 녹십자홀딩스 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법
EP3275897A1 (en) 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
DE3640513A1 (de) * 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
EP0338229B1 (de) * 1988-04-19 1993-06-16 Biotest Pharma Gmbh Präparat mit Antikörperaktivität und breitem Wirkungsspektrum, daraus bestehende oder diese enthaltende Mittel und deren Verwendung zur Behandlung von bakteriell oder toxin-bedingten Erkrankungen und zur Bekämpfung von Protozoen
FR2632308B1 (fr) * 1988-06-07 1991-08-16 Fondation Nale Transfusion San Procede et installation de fractionnement en continu de proteines vegetales animales ou humaines
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process

Also Published As

Publication number Publication date
JPH06107561A (ja) 1994-04-19
EP0447585B1 (de) 1995-05-03
US5164487A (en) 1992-11-17
ES2074490T5 (es) 2004-02-16
ATE122054T1 (de) 1995-05-15
EP0447585A1 (de) 1991-09-25
DK0447585T3 (da) 1995-05-29
EP0447585B2 (de) 2003-05-07
DE59009020D1 (de) 1995-06-08
DK0447585T4 (da) 2003-09-01

Similar Documents

Publication Publication Date Title
ES2074490T3 (es) Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.
SE8504967D0 (sv) A pharmaceutical composition and a method of treating the body
ES2168395T3 (es) Nueva formulacion antitrombotica, procedimiento para su preparacion y utilizacion de la misma.
DE3752112T2 (de) Verwendung von Inositoltriphosphat zur Behandlung von Entzündungen
KR900701261A (ko) 비만증 치료방법
DK0457849T3 (da) Klæbemiddel til elektrotransport
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
ES2067624T3 (es) Un procedimiento de preparacion de una composicion farmaceutica liquida para administracion nasal.
BR9201718A (pt) Concentrado de fator xi da coagulacao sanguinea de alta atividade especifica,apropriado para uso terapeutico e seu processo de preparacao
PT95212A (pt) Processo para a preparacao de uma composicao para uso topico para o tratamento da fragilidade capilar, contendo defibrotide
ES2055761T3 (es) Procedimiento para la concentracion de los factores de coagulacion de la sangre ii, vii, ix y x.
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
ES2093811T3 (es) Medicamento que contiene proteina c.
DE69115687T2 (de) Verwendung von spezifischen Fettsäuren zur Herstellung eines Medikaments zur Verabreichung durch Iontophorese
IL101675A0 (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
MX9203374A (es) Composicion farmaceutica que contiene l-alfa-glicerofosforilcolina.
IT8748117A0 (it) Derivati di glicina quali agenti preventivi e terapeutici per le complicanze diabetiche
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
ATE244011T1 (de) Unterdrückung der thromboxanspiegel durch perkutane verabreichung von aspirin
AU2525488A (en) Use of metalloporphyrins to reverse the toxic effect of tumor therapy
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
AR227320A1 (es) Una composicion apropiada para usarla en el tratamiento de fibras de vidrio,metodo para tratar dichas fibras con la mencionada composicion,fibras de vidrio tratadas,y cuerpo compuesto que contiene a dichas fibras
DE3879837D1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
AR013498A1 (es) Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 447585

Country of ref document: ES